source
- Aviceda Therapeutics to wind down after Phase 2 failure in geographic atrophy programAviceda Therapeutics, a biotech focused on geographic atrophy, announced it is winding down operations. The decision follows a Phase 2 trial that did not meet its endpoints, halting plans to move…
- FDA launches new office in CDER to modernize clinical trialsThe FDA announced the creation of a new office within its Center for Drug Evaluation and Research (CDER) dedicated to modernizing clinical trials. The office aims to accelerate the design and exec…